Congruence Therapeutics

Dewpoint Therapeutics

This biotechnology company develops condensate-modifying small molecule drugs for patients with oncology, neurodegenerative, cardiopulmonary and metabolic diseases using an AI-enabled discovery platform.

Nimbus Therapeutics

This clinical-stage biotechnology company develops small molecule medicines for patients with cancer, immunology, and metabolic diseases using an AI-enhanced computational discovery engine.

Auron Therapeutics

This company develops small-molecule drugs using an AI-powered platform to treat patients with cancer and inflammatory diseases.

Ten63 Therapeutics

This company develops small-molecule drugs for pharmaceutical partners and patients using a generative artificial intelligence and physics-based chemistry platform to treat undruggable protein targets.

CHARM Therapeutics

This company develops small-molecule drugs for cancer patients using a deep-learning platform that models protein-ligand interactions to identify novel therapeutic targets.

Gain Therapeutics

This biotechnology company develops allosteric small molecule therapies for patients with neurodegenerative diseases and rare genetic disorders using an artificial intelligence drug discovery platform.

Frontier Medicines

This biopharmaceutical company develops small-molecule precision medicines targeting undruggable proteins for patients with cancer and immunological diseases.

Pragma Bio

This company develops a machine learning platform to discover and manufacture microbiome-derived small molecule medicines for patients with immunological disorders and cancer.